Coronary heart disease
Conditions
Interventions
Pravastatin group: Pravastatin 40mg as a once per day dose is administered. The average duration of follow-up will be more than 5 years.
Placebo group: Matching placebo once daily is administered.
Sponsors
The CARE Investigators
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Men and postmenopausal women were eligible if they had had an acute myocardial infarction between 3 and 20 months and and had plasma total cholesterol levels of less than 240 mg per deciliter, LDL cholesterol levels of 115 to 174 mg per deciliter, and fasting triglyceride levels of less than 350 mg per deciliter.
Exclusion criteria
Exclusion criteria: Ejection fraction < 25%. Overt congestive heart failure (symptomatic despite drug therapy). Prior sensitivity to HMG-CoA reductase inhibitors. Nephrotic syndrome or other renal disease. Excessive ethanol intake as > 3 drinks per day. Hepatobiliary disease. Malignancy. History of immune disorders. Untreated and uncontrolled endocrine disease. Significant gastrointestinal disease. Treatment with other lipid-lowering drug. Severe valvular heart disease requiring surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Death from coronary heart disease (including fatal myocardial infarction, either definite or probable; sudden death; death during a coronary intervention; and death from other coronary causes) or a symptomatic (unless during noncardiac surgery) nonfatal myocardial infarction confirmed by serum creatine kinase measurements. | — |
Countries
North America
Contacts
Public ContactFrank M. Sacks
Harvard School of Public Health Department of Nutrition
Outcome results
None listed